OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
The acquisition marks a pivotal expansion for the company into the US market.
The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.
January 16, 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
January 15, 2024
The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.
Harmonization of global regulations fosters innovation and ensures quality medicines.
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.
FDA is anticipating how AI may advance manufacturing and improve supply chain security.